
How RSV manipulates the immune response in respiratory cells
TWINCORE researchers investigate gene activity in host cells

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal

The 23rd doctoral thesis to receive an award at TWINCORE
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Vandenabeele L, Ayanwale A, Pietschmann T, Nilsson-Payant B
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Berg K, Haid S, Vafadarnejad E, Carpentier A, Geffers R, Wiegmann B, Saliba A, Erhard F, Pietschmann T
The project investigates how HCMV is recognized by the immune system and which mechanisms the virus uses to camouflage itself. The aim is to understand the immune reactions and develop therapies for severely affected patients.
In this project, antibodies that help to ward off infections are being investigated in more detail. The aim is to find characteristics that have a protective effect against certain pathogens by comparing different antibody profiles in infections and vaccinations.
This project focuses on lung infections such as influenza, COVID-19, pneumonia and tuberculosis in order to improve diagnostics, patient stratification and therapy. RNA molecules and metabolites are being investigated as biomarkers and complementary therapies.
We develop high-throughput screening assays to identify antiviral molecules against RSV and SARS-CoV-2. We use compound libraries, investigate new mechanisms of action and strive for innovative therapies.

